RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q1 FY22 results · Apr–Jun 2021
RPG Life Sciences reported revenue from operations of ₹108.13 crore (up 18.0% from Q1 FY21) and net profit of ₹13.58 crore (up 49.9% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a standalone basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 108.13 | 91.65 | +18.0% | 92.76 | +16.6% |
| Other income | 0.41 | 0.45 | −8.9% | 0.30 | +36.7% |
| Total income | 108.54 | 92.10 | +17.9% | 93.06 | +16.6% |
| Profit before tax | 19.27 | 12.83 | +50.2% | 8.95 | +115.3% |
| Net profit for the period | 13.58 | 9.06 | +49.9% | 6.92 | +96.2% |
| EPS, basic (₹) | 8.21 | 5.48 | +49.8% | 4.18 | +96.4% |
| Net margin (%) | 12.6 | 9.9 | 7.5 |
Standalone
- Filed with BSE
- 28 Jul 2021, 19:41 IST
- Board meeting
- 28 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE